Wegovy® weight loss pens
Wegovy® weight loss pens
Wegovy® weight loss pens
- Weekly weight loss injection that suppresses appetite and reduces cravings
- With lifestyle changes around 85% of people lose weight
- From £42.25 a week
Wegovy® is a weight loss drug which is used to help people with high body mass indexes (BMI) lose weight. Our clinicians will check your BMI, before they prescribe this treatment.
Wegovy is a new drug with the active ingredient, semaglutide, that can be used to help people lose weight by around 15% (over 68 weeks).
What is Wegovy®?
Wegovy® is a weight loss drug containing the active ingredient, semaglutide. It’s injected into the body once a week to help you lose weight. Wegovy® is thought to be an effective weight loss drug when used alongside a healthy, reduced-calorie diet and increased exercise.
The drug has recently been approved in the UK and is available now. It was approved in the USA in 2021.
How does Wegovy® work?
Wegovy® essentially works by suppressing the appetite and regulating food intake. The active ingredient, semaglutide, mimics the action of the hormone that’s involved in regulating appetite. This means you feel fuller for longer and less hungry. This can help you to eat less and hopefully lose weight.
The starting dose is 0.25mg, if you’re tolerating the treatment after 4 weeks you’ll step up in dose. The highest dose 2.4mg, which has seen positive results in 2 year trials.
Wegovy® works best when it’s taken at the same time as making lifestyle changes (healthier diet and increased exercise). In fact, around 85% of users lost at least 5% of their weight, compared to just 40% losing 5% when no lifestyle changes were made.
Where can I get Wegovy®?
You can’t get Wegovy® over the counter as it’s a prescription-only medication. This means you’ll need to speak to a healthcare professional, usually via an online consultation. They’ll make sure Wegovy® is the right weight loss treatment for you and it’s safe to take. There are weight loss medications like Orlistat which you can get over the counter.
Using our Wegovy® service
If you’d like to request Wegovy® for weight loss, please complete our online consultation. During this we’ll ask you a series of questions to assess if the treatment is right for you and your weight loss journey.
If it’s your first time ordering from us, you’ll also need to upload a video showing your ID and weight, so we can verify your identity and BMI. If you’re prescribed, you can have your treatment delivered the next day.
Please note - if you live in Northern Ireland, it’s important you know that Wegovy will be prescribed for you off label. This means the manufacturers haven’t licenced the use of Wegovy in Northern Ireland yet. We will still ensure Wegovy is safe for you to take according to the guidelines we use in Great Britain.
Taking Wegovy®
You inject Wegovy® just once a week into your tummy, thigh or upper arm. Read our article to find out more about how to inject yourself.
Wegovy® injections come in a variety of doses. Depending on where you are in your Wegovy® journey, you will need to take a different dose.
The dose is gradually increased to make sure you cope with any potential side effects until you get to a maintenance dose, this process is known as titration. Find out how to know when to increase your dose.
If all goes to plan and you can tolerate the treatment, the dosing schedule will be as follows:
- Weeks 1-4: 0.25mg weekly
- Weeks 5-8: 0.5mg weekly
- Weeks 9-12: 1mg weekly
- Weeks 13-16: 1.7mg weekly
- Weeks 17 onwards: 2.4mg weekly
How effective is Wegovy®?
When Wegovy® is combined with a reduced calorie diet and increased exercise, a 68-week study has shown that:
- Around 85% of people lost more than 5% of their body weight
- 66% of people lost more than 10% of their body weight
- 48% of people lost more than 15% of their body weight
- 30% of people lost more than 20% of their body weight
This compares to just 60% of people losing 5% of their weight when taking Saxenda® along with a reduced calorie diet and physical activity counselling.
